| 價(jià)格 | 詢價(jià) |
| 包裝 | 1支 |
| 最小起訂量 | 1支 |
| 發(fā)貨地 | 湖北 |
| 更新日期 | 2026-07-08 |
| 中文名稱:PD-ECGF兔多抗 | 英文名稱:PD-ECGF Rabbit Polyclonal Antibody |
| 品牌: EnkiLife | 產(chǎn)地: 中國 |
| 保存條件: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. | 產(chǎn)品類別: 抗體 |
| 是否進(jìn)口: 否 | 用途: 科研 |
產(chǎn)品概述
產(chǎn)品性能
免疫原
產(chǎn)品應(yīng)用
研究背景
This gene encodes an angiogenic factor which promotes angiogenesis in vivo and stimulates the in vitro growth of a variety of endothelial cells. It has a highly restricted target cell specificity acting only on endothelial cells. Mutations in this gene have been associated with mitochondrial neurogastrointestinal encephalomyopathy. Multiple alternatively spliced transcript variants have been identified. [provided by RefSeq, Apr 2012],catalytic activity:Thymidine + phosphate = thymine + 2-deoxy-alpha-D-ribose 1-phosphate.,disease:Defects in TYMP are the cause of mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) [MIM:603041]; also known as myoneurogastrointestinal encephalomyopathy. MNGIE is an autosomal recessive disease associated with multiple deletions of skeletal muscle mitochondrial DNA (MtDNA). It is clinically characterized by onset between the second and fifth decades of life, ptosis, progressive external ophthalmoplegia, gastrointestinal dysmotility (often pseudoobstruction), diffuse leukoencephalopathy, thin body habitus, peripheral neuropathy, and myopathy.,function:Catalyzes the reversible phosphorolysis of thymidine. The produced molecules are then utilized as carbon and energy sources or in the rescue of pyrimidine bases for nucleotide synthesis.,function:May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro.,pathway:Pyrimidine metabolism; dTMP biosynthesis via salvage pathway; dTMP from thymine: step 1/2.,similarity:Belongs to the thymidine/pyrimidine-nucleoside phosphorylase family.,subunit:Homodimer.,
研究領(lǐng)域
Pyrimidine metabolism;Drug metabolism;Bladder cancer;
| 成立日期 | 2024-08-02 (2年) | 注冊資本 | 271萬人民幣 |
| 員工人數(shù) | 10-50人 | 年?duì)I業(yè)額 | ¥ 100萬-300萬 |
| 主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),癌癥研究,細(xì)胞生物學(xué) | 經(jīng)營模式 | 工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
|---|---|---|---|---|
| 詢價(jià) |
VIP4年
|
武漢佰樂博生物技術(shù)有限公司
|
2026-07-29 | |
| ¥3750 |
武漢艾美捷科技有限公司
|
2026-07-28 | ||
| 詢價(jià) |
碧云天生物技術(shù)有限公司
|
2026-07-28 |